Vir Biotechnology: Expanded Hepatitis Pipeline And COVID-19 Revenue Expected - Seeking Alpha

Retrieved on: 2022-05-02 21:19:49

Tags for this article:

Medical specialties

Clinical medicine

Branches of biology

Antiviral drugs

Infectious causes of cancer

Click the tags to see associated articles and topics

Vir Biotechnology: Expanded Hepatitis Pipeline And COVID-19 Revenue Expected - Seeking Alpha. View article details on HISWAI: https://seekingalpha.com/article/4505896-vir-biotechnology-expanded-hepatitis-pipeline-and-covid-revenue-commitments-expected

Excerpt

The point of PEG-IFN-a as an immunomodulating drug is to modify (improve) an immune response against Hepatitis B. The combination of VIR-2218 plus ...

Article found on: seekingalpha.com

View Original Article